Wolverine Stack research vial
SwissNova Labs
Wolverine Stack · 5mg BPC-157 + 5mg TB-500
≥99% Purity · COA Included
Recovery

Wolverine Stack

Purity: 99%+
Size: 5mg BPC-157 + 5mg TB-500
Grade: Research
Form: Lyophilized
SwissNova Labs · Research Grade
RecoveryNEW!

Wolverine Stack

Multi-peptide regenerative stack for accelerated healing and tissue repair.

Dual-mechanism repair — combines BPC-157 angiogenic signaling with TB-500 systemic cell migrationTendon & ligament healing — BPC-157 shown to accelerate connective tissue repair via VEGFR2 and FAK pathwaysSystemic distribution — TB-500 travels via bloodstream to reach distant or deep injury sitesAnti-inflammatory — both BPC-157 and TB-500 suppress inflammatory cytokines (IL-6, TNF-α)
Strength5mg BPC-157 + 5mg TB-500
$90.00
5mg BPC-157 + 5mg TB-500 · Research use only
Compound Specifications
Purity99%+
Molecular WeightMulti-component
Vial Size5mg BPC-157 + 5mg TB-500
SequenceBPC-157 + TB-500 combination
Vial Supply
Duration~6 weeks supply
Week 1Week 6
Why Researchers Choose This Compound

Key Benefits

01
Dual-mechanism repair

combines BPC-157 angiogenic signaling with TB-500 systemic cell migration

02
Tendon & ligament healing

BPC-157 shown to accelerate connective tissue repair via VEGFR2 and FAK pathways

03
Systemic distribution

TB-500 travels via bloodstream to reach distant or deep injury sites

04
Anti-inflammatory

both BPC-157 and TB-500 suppress inflammatory cytokines (IL-6, TNF-α)

Mechanism of Action

Active Signaling Pathway

BioHuman Research Dossier
Human Data AvailableResearch use only — not for human consumption

Investigated Pathways

AngiogenesisCollagen SynthesisMucosal Healing

Proposed Mechanism

The Wolverine Stack combines two complementary repair mechanisms: BPC-157 activates growth factor receptors (VEGFR2, FAK/paxillin) and promotes angiogenesis at injury sites; TB-500 (Thymosin Beta-4) sequesters G-actin for cytoskeletal remodeling and distributes systemically to reach distant injury sites via the bloodstream.

Research Highlights

  • BPC-157 shown to heal tendon-to-bone injuries 2× faster in rodent models via VEGFR2 activation
  • TB-500 demonstrated systemic tissue repair via blood-borne distribution to distant injury sites
  • BPC-157 provides localized angiogenic signaling; TB-500 provides systemic anti-inflammatory coverage
  • Stack combination provides complementary and synergistic healing mechanisms across multiple tissue types
Human Data AvailableEvidence Strength

Human observational or open-label study data exists. Controlled trial data may be limited. Not a treatment recommendation.

Research FocusGut & GI
Gut & GI body system research map
Gut & GILiver

For laboratory research only

All Research Systems →

For research use only — not for human consumption. No treatment claims.

Full Research Hub →
Supply Calculator

How long will one vial last?

Based on standard research protocols, here's exactly what to expect from a single 5mg BPC-157 + 5mg TB-500 vial — and when to plan your next order.

One vial lasts
6
weeks
Approximately 1 month of supply at standard protocol volumes.
Reorder around week 5 to avoid running out
Your supply timeline5mg BPC-157 + 5mg TB-500 vial
Start↑ ReorderWeek 6 — empty
1
2
3
4
5
6
Active supplyReorder week

Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.

Research Literature

Scientific Background

Mechanism of Action

The Wolverine Stack combines two complementary repair mechanisms: BPC-157 activates growth factor receptors (VEGFR2, FAK/paxillin) and promotes angiogenesis at injury sites; TB-500 (Thymosin Beta-4) sequesters G-actin for cytoskeletal remodeling and distributes systemically to reach distant injury sites via the bloodstream.

Clinical Context

Both components of the Wolverine Stack have independent preclinical validation. The combination is designed to address tissue repair at multiple levels — structural (BPC-157) and systemic/vascular (TB-500). The classic BPC-157 + TB-500 pairing is one of the most widely used recovery protocols in peptide research.

Research Highlights

  • BPC-157 shown to heal tendon-to-bone injuries 2× faster in rodent models via VEGFR2 activation
  • TB-500 demonstrated systemic tissue repair via blood-borne distribution to distant injury sites
  • BPC-157 provides localized angiogenic signaling; TB-500 provides systemic anti-inflammatory coverage
  • Stack combination provides complementary and synergistic healing mechanisms across multiple tissue types

Storage & Reconstitution

Store lyophilized powder at -20°C. Reconstitute each vial separately with bacteriostatic water (2 mL per vial). After reconstitution, both can be drawn into the same syringe for co-administration.

Combo Vial

Reconstitution & Dosage Guide

Single Combo Vial — One Reconstitution

BPC-157 (5 mg) and TB-500 (5 mg) are pre-blended in one vial. Add 2 mL BAC water to the single vial. One injection delivers both peptides simultaneously — no separate draws needed.

Reconstitution

Vial contents

10 mg total

BAC water

2 mL

Concentration

5 mg/mL

BAC vials needed

1 vial

Each 0.1 mL drawn = 500 mcg BPC-157 + 500 mcg TB-500. Both peptides are delivered in every injection at a 1:1 ratio.

Syringe Draw (U-100)

10IU · 0.10 mL

BPC-157 500 mcg + TB-500 500 mcg

Start dose

20IU · 0.20 mL

BPC-157 1 mg + TB-500 1 mg

Standard dose

40IU · 0.40 mL

BPC-157 2 mg + TB-500 2 mg

Full dose

Storage after reconstitution: 14–28 days at 2–8 °C. Protect from light.

Doses per vial: 10 doses at start dose (10 IU) · 5 doses at standard (20 IU) · 2–3 doses at full dose (40 IU)

Weekly Protocol Schedule

Weeks 1–4 — Loading Phase

20–40 IU (0.20–0.40 mL) daily
1 mg–2 mg of each peptide per injection

Weeks 5–12 — Maintenance Phase

10–20 IU (0.10–0.20 mL) daily
500 mcg–1 mg of each peptide per injection

Injection site: Abdomen (periumbilical fat) preferred. TB-500 distributes systemically so any SubQ site works — no need to inject near the injury.

Peer-Reviewed Research

Key Studies

2018Current Pharmaceutical Design

Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract

Sikiric P et al.

BPC-157 component demonstrated comprehensive healing of tendon-to-bone injuries via VEGFR2 and FAK pathway activation.

PubMed →
2012Annals of the New York Academy of Sciences

Thymosin beta4 promotes cardiac repair after myocardial infarction

Goldstein AL et al.

TB-500 component demonstrated systemic tissue repair via blood-borne distribution, reaching distant injury sites.

PubMed →
2019Current Pharmaceutical Design

BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing

Gwyer D et al.

Combined recovery review confirming synergistic healing mechanisms of BPC-157 and TB-500 across multiple tissue types.

PubMed →
Absorption & Distribution

Pharmacokinetics

PK Parameters
BioavailabilityCombined: BPC-157 ~100% SubQ; TB-500 ~85–95% SubQ
Peak PlasmaBPC-157: 30–60 min; TB-500: 2–4 hours
Half-lifeBPC-157: ~4h; TB-500: ~6–8h; complementary half-lives provide sustained repair signaling
ClearanceProteolytic degradation for both components; renal clearance
Volume of DistributionBPC-157: ~0.3 L/kg; TB-500: ~0.5 L/kg
What this means

Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.

The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.

Molecular Targets

Receptor Binding Profile

VEGFR2 (BPC-157)Upregulation

Angiogenesis and new blood vessel formation at injury sites

FAK/paxillin pathway (BPC-157)Activation

Cell migration and proliferation for tissue repair

G-actin / β4 integrin (TB-500)Sequestration/Activation

Cytoskeletal remodeling and systemic cell migration

NF-κB (TB-500)Inhibition

Anti-inflammatory cytokine suppression (IL-6, TNF-α)

Safety Profile

Side Effects & Adverse Events

Common
  • Injection site reactions
  • Mild fatigue
Uncommon
  • Headache
  • Nausea
Serious
  • None documented for either component
NOTE:Combined safety profile of BPC-157 and TB-500. Both have excellent individual safety records across 30+ years of research.
Research Safety

Contraindications & Interactions

Absolute Contraindications
Active malignancy (pro-angiogenic components — both BPC-157 and TB-500 promote angiogenesis)
Relative Contraindications
Pregnancy (insufficient data)Concurrent anticoagulant therapy
Drug Interactions
Anticoagulants (monitor)NSAIDs (BPC-157 may potentiate GI protection)
NOTE:Individual component contraindications apply. Pro-angiogenic properties warrant caution in oncology contexts.
Stack Protocols

Synergistic Compounds

GHK-Cu

GHK-Cu's gene expression reset and collagen synthesis add a third healing mechanism to the BPC-157 + TB-500 stack.

Wolverine Stack + GHK-Cu 1 mg SubQ daily for comprehensive tissue repair.

View Compound →
Sermorelin

GH/IGF-1 elevation from sermorelin synergizes with the Wolverine Stack's repair mechanisms for enhanced recovery.

Wolverine Stack SubQ + Sermorelin 300 mcg pre-sleep SubQ.

View Compound →
Sourcing & Testing

Transparent Global Sourcing

🇨🇳

Manufactured

Sourced through our manufacturing partner in China

🧪

Independent Testing

Analytical reports available from Janoshik Analytical

🔍

Batch Verification

Batch-specific COAs with online verification via janoshik.com

🇺🇸

US Fulfillment

Orders fulfilled from the United States

Testing documentation varies by product and batch. Customers may review available reports and verification information before ordering. COA task numbers and verification keys can be confirmed directly at janoshik.com/verification. For research use only — not for human consumption.
RESEARCH USE ONLY:All products are sold strictly for in vitro research and laboratory use. Not intended for human consumption, clinical use, diagnosis, treatment, or prevention of any disease or condition. By purchasing, you confirm you are a qualified researcher and will use these compounds in accordance with all applicable laws and regulations.